Brian Christopher Booth

US Patent:

20220356263, Nov 10, 2022

Filed:

Jan 13, 2022

Appl. No.:

17/575420

Inventors:

- Waltham MA, US
Brian Booth - Waltham MA, US
Boopathy Ramakrishnan - Waltham MA, US
Andrew Wollacott - Waltham MA, US
Gregory Babcock - Waltham MA, US
Zachary Shriver - Waltham MA, US

International Classification:

C07K 16/28
A61P 37/02

Abstract:

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.